Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PK, safety and tolerability study of Lu AF28996 in Japanese patients with Parkinson's disease
jRCT2061230047Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lu AF28996 in Parkinson's disease (PD), sponsored by Lundbeck. Primary endpoint: Safety, tolerability, and pharmacokinetics of Lu AF28996. Started Sep 2023; status: completed.
02
Drugs
Lu AF28996
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2061230047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230047.